

# Jay Giri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6260196/publications.pdf>

Version: 2024-02-01

174  
papers

7,928  
citations

125106

35  
h-index

62345

84  
g-index

192  
all docs

192  
docs citations

192  
times ranked

12746  
citing authors

#	ARTICLE	IF	CITATIONS
1	Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas. JAMA Cardiology, 2022, 7, 150.	3.0	37
2	Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions. Personalized Medicine, 2022, 19, 41-49.	0.8	0
3	Economic Considerations in Access to Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011489.	1.4	8
4	Attitudes toward pharmacogenetics in patients undergoing CYP2C19 testing following percutaneous coronary intervention. Personalized Medicine, 2022, 19, 93-101.	0.8	2
5	CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. Journal of the American Heart Association, 2022, 11, e024159.	1.6	24
6	Did the COVID-19 Pandemic Just Turn TAVR Into an Outpatient Procedure?. JACC: Cardiovascular Interventions, 2022, 15, 599-602.	1.1	2
7	Impact of COVID-19 pandemic on STEMI care: An expanded analysis from the United States. Catheterization and Cardiovascular Interventions, 2021, 98, 217-222.	0.7	70
8	Observational study assessing changes in timing of readmissions around postdischarge day 30 associated with the introduction of the Hospital Readmissions Reduction Program. BMJ Quality and Safety, 2021, 30, 493-499.	1.8	2
9	Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair. American Heart Journal, 2021, 232, 1-9.	1.2	6
10	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2021, 109, 705-715.	2.3	25
11	Evolution and Outcomes of Premature Coronary Artery Disease. Current Cardiology Reports, 2021, 23, 36.	1.3	8
12	Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease. Journal of the American Heart Association, 2021, 10, e019331.	1.6	19
13	Trends in Coded Indications for Percutaneous Coronary Interventions in Medicare and the Veterans Affairs After Implementation of Hospital-Level Reporting of Appropriate Use Criteria. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006887.	0.9	2
14	Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2021, 14, e010032.	1.4	23
15	Variability in Reported Percutaneous Coronary Intervention Mortality Among Physicians Practicing at Multiple Sites in New York State. JAMA Cardiology, 2021, 6, 477.	3.0	2
16	Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. JAMA Network Open, 2021, 4, e216139.	2.8	187
17	Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. Circulation: Heart Failure, 2021, 14, e008277.	1.6	1
18	Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 1533-1545.	1.9	21

#	ARTICLE	IF	CITATIONS
19	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq1 1 0.784314 rgBT /Overlock	6.3	197
20	Reporting of Percutaneous Coronary Interventions Site-Specific Mortalityâ€”Reply. JAMA Cardiology, 2021, 6, 1344.	3.0	0
21	Lack of Association Between Percutaneous Coronary Intervention and Transcatheter Aortic Valve Replacement Outcomes in New York Hospitals. Circulation: Cardiovascular Interventions, 2021, 14, e010750.	1.4	0
22	Analysis of Costs and Payments for Inferior Vena Cava Filter Retrieval in the Medicare Population. Journal of Vascular and Interventional Radiology, 2021, 32, 1164-1169.	0.2	1
23	Geographic and Socioeconomic Disparities in Major Lower Extremity Amputation Rates in Metropolitan Areas. Journal of the American Heart Association, 2021, 10, e021456.	1.6	42
24	Dual-Layered Stents. JACC: Cardiovascular Interventions, 2021, 14, 1924-1925.	1.1	2
25	Mechanical Complications in ST-Elevation Myocardial Infarction (STEMI) Based on Different Reperfusion Strategies. American Journal of Cardiology, 2021, 156, 79-84.	0.7	5
26	Volume, outcomes, and â€”Centers of Excellenceâ€”™ for pulmonary embolism care. Vascular Medicine, 2021, 26, 47-49.	0.8	4
27	National trends in utilization of thrombolytic therapy for acute pulmonary embolism. Vascular Medicine, 2021, , 1358863X2110485.	0.8	0
28	Socioeconomic and Geographic Characteristics of Hospitals Establishing Transcatheter Aortic Valve Replacement Programs, 2012â€”2018. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008260.	0.9	27
29	Myocardial Infarction During the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2021, 326, 1916.	3.8	22
30	Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S.Â—Practice With ISCHEMIA Trial Population. JACC: Cardiovascular Interventions, 2021, 14, 2344-2349.	1.1	11
31	Current interventional therapies in acute pulmonary embolism. Progress in Cardiovascular Diseases, 2021, 69, 54-61.	1.6	3
32	Hospital-Level Percutaneous Coronary Intervention Performance With SimulatedÂ—Risk Avoidance. Journal of the American College of Cardiology, 2021, 78, 2213-2217.	1.2	1
33	Coronary Stents. JACC: Cardiovascular Interventions, 2021, 14, 2474-2476.	1.1	2
34	1 Month of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2021, 78, 2073-2075.	1.2	0
35	Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum, 2021, 2, e214182.	1.0	58
36	Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy. Circulation: Cardiovascular Interventions, 2021, 14, e011232.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Strategies for radiation exposureâ€sparing in fluoroscopically guided invasive cardiovascular procedures. Catheterization and Cardiovascular Interventions, 2020, 95, 118-127.	0.7	7
38	Bicuspid Aortic Valve Stenosis andÂSimulation. JACC: Cardiovascular Interventions, 2020, 13, 193-195.	1.1	0
39	Management of Acute Pulmonary Embolism. Current Cardiovascular Risk Reports, 2020, 14, 24.	0.8	12
40	Peri-Procedural Stroke With Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2020, 13, 2178-2180.	1.1	1
41	Predicting the Unpredictable in Coronary Artery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1917-1919.	1.1	1
42	Thrombosis in <scp>COVID</scp>â€19. American Journal of Hematology, 2020, 95, 1578-1589.	2.0	235
43	Comparison of 4 Acute Pulmonary Embolism Mortality Risk Scores in Patients Evaluated by Pulmonary Embolism Response Teams. JAMA Network Open, 2020, 3, e2010779.	2.8	26
44	Current trends in utilization of fibrinolyticâ€based reperfusion strategies and bleeding outcomes in <scp>ST</scp>â€elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2020, 96, E566-E567.	0.7	1
45	Association Between 90-Minute Door-to-Balloon Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice. Circulation: Cardiovascular Interventions, 2020, 13, e009179.	1.4	9
46	North American COVID-19 ST-Segment-Elevation Myocardial Infarction (NACMI) registry: Rationale, design, and implications. American Heart Journal, 2020, 227, 11-18.	1.2	33
47	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	1.8	206
48	Active smoking is associated with higher rates of incomplete wound healing after endovascular treatment of critical limb ischemia. Vascular Medicine, 2020, 25, 427-435.	0.8	7
49	Catheter-Based Therapies in Acute Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2020, 13, e009353.	1.4	8
50	Considerations for cardiac catheterization laboratory procedures during the <scp>COVID</scp>â€19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (<scp><i>SCAI ELM</i></scp>) Members and Graduates. Catheterization and Cardiovascular Interventions, 2020, 96, 586-597.	0.7	89
51	Mortality trends around the oneâ€year survival mark after heart, liver, and lung transplantation in the United States. Clinical Transplantation, 2020, 34, e13852.	0.8	3
52	Catheter-Directed Thrombolysis With Ultrasound Assistance for Acute Pulmonary Embolism. Chest, 2020, 157, 491-492.	0.4	0
53	Percutaneous recanalization of superior vena cava occlusions for cardiac implantable electronic device implantation: Tools and techniques. Heart Rhythm, 2020, 17, 2010-2015.	0.3	3
54	One-Year Outcomes of Percutaneous Coronary Intervention in Patients with End-Stage Liver Disease. Clinical Medicine Insights: Cardiology, 2020, 14, 117954682090149.	0.6	14

#	ARTICLE	IF	CITATIONS
55	Interventional Therapies in Acute Pulmonary Embolism. <i>Interventional Cardiology Clinics</i> , 2020, 9, 229-241.	0.2	5
56	Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002640.	1.6	39
57	Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: A systematic review and meta-analysis. <i>Vascular Medicine</i> , 2020, 25, 106-117.	0.8	50
58	Performance of Hospitals When Assessing Disease-Based Mortality Compared With Procedural Mortality for Patients With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2020, 5, 765.	3.0	10
59	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
60	Patient and Staff Perceptions of Universal Severe Acute Respiratory Syndrome Coronavirus 2 Screening Prior to Cardiac Catheterization and Electrophysiology Laboratory Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009975.	1.4	1
61	Wire countertraction for sheath placement through stenotic and tortuous veins: The "body flossing" technique. <i>Heart Rhythm</i> , 2020, 1, 21-26.	0.6	2
62	Impact of Artificial Intelligence on Interventional Cardiology. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1293-1303.	1.1	76
63	Self-Expanding Valve System for Treatment of Native Aortic Regurgitation by Transcatheter Aortic Valve Implantation (from the STS/ACC TVT Registry). <i>American Journal of Cardiology</i> , 2019, 124, 781-788.	0.7	23
64	Use of Intracardiac Echocardiography During Transvenous Lead Extraction to Avoid a Catastrophic Injury. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 744-745.	1.3	6
65	Balancing Weight Loss and Sarcopenia in Elderly Patients With Peripheral Artery Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e013200.	1.6	15
66	Perceptions of Public and Nonpublic Reporting of Interventional Cardiology Outcomes and Its Impact on Practice: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. <i>Journal of the American Heart Association</i> , 2019, 8, e014212.	1.6	4
67	Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 140, e774-e801.	1.6	241
68	Etiologies, trends, and predictors of readmission in ST-elevation myocardial infarction patients undergoing multivessel percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 905-914.	0.7	15
69	Association of Medicaid Expansion With Cardiovascular Mortality. <i>JAMA Cardiology</i> , 2019, 4, 671.	3.0	102
70	Effect of Public Reporting on the Utilization of Coronary Angiography After Out-of-Hospital Cardiac Arrest. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007564.	1.4	7
71	Centers of Excellence Designations, Clinical Outcomes, and Characteristics of Hospitals Performing Percutaneous Coronary Interventions. <i>JAMA Internal Medicine</i> , 2019, 179, 1138.	2.6	5
72	Hospital-Specific Mortality for Acute Myocardial Infarction Versus Emergency Percutaneous Coronary Intervention in New York State. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 898-899.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Soluble FMS-Like Tyrosine Kinase-1 Is a Circulating Biomarker Associated With Calcific Aortic Stenosis. Journal of the American College of Cardiology, 2019, 73, 1364-1365.	1.2	2
74	Keep it simple? Half-dose systemic thrombolysis or catheter-directed thrombolysis for pulmonary embolism. Vascular Medicine, 2019, 24, 110-111.	0.8	5
75	Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute pulmonary embolism: A multicenter comparison of patient-centered outcomes. Vascular Medicine, 2019, 24, 241-247.	0.8	39
76	Racial, Ethnic, and Socioeconomic Inequities in the Prescription of Direct Oral Anticoagulants in Patients With Venous Thromboembolism in the United States. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005600.	0.9	42
77	Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension. Journal of the American College of Cardiology, 2019, 73, 1633-1642.	1.2	69
78	Assessing the Long-term Safety of Endovascular Therapies—The Case of Peripheral Paclitaxel-Coated Devices. JAMA Cardiology, 2019, 4, 340.	3.0	4
79	Reexamining the Open-Vein Hypothesis for Acute Deep Venous Thrombosis. Circulation, 2019, 139, 1174-1176.	1.6	14
80	Paradigm Shifts in the Treatment of Stable Ischemic Heart Disease. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005388.	0.9	0
81	The Pros and Cons of Percutaneous Coronary Intervention in Patients With Cancer. JACC: CardioOncology, 2019, 1, 156-158.	1.7	0
82	The CREST-2 Registry. Journal of the American College of Cardiology, 2019, 74, 3080-3082.	1.2	2
83	Strength of Evidence Underlying the American Heart Association/American College of Cardiology Guidelines on Endovascular and Surgical Treatment of Peripheral Vascular Disease. Circulation: Cardiovascular Interventions, 2019, 12, e007244.	1.4	16
84	Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009–2016. Circulation: Cardiovascular Interventions, 2019, 12, e007434.	1.4	15
85	Trends in catheter-directed thrombolysis and systemic thrombolysis for the treatment of pulmonary embolism. American Heart Journal, 2019, 207, 83-85.	1.2	14
86	Association of Tricuspid Regurgitation With Transcatheter Aortic Valve Replacement Outcomes: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Annals of Thoracic Surgery, 2018, 105, 1121-1128.	0.7	37
87	Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 17.	0.4	1
88	Treatment of submassive and massive pulmonary embolism: a clinical practice survey from the second annual meeting of the Pulmonary Embolism Response Team Consortium. Journal of Thrombosis and Thrombolysis, 2018, 46, 39-49.	1.0	19
89	Is it Time to Abandon Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation—Anticoagulation?. JACC: Cardiovascular Interventions, 2018, 11, 635-637.	1.1	2
90	Hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: A meta-analysis. Catheterization and Cardiovascular Interventions, 2018, 91, 203-212.	0.7	45

#	ARTICLE	IF	CITATIONS
91	Stroke After Transcatheter Aortic Valve Replacement: Incidence, Definitions, Etiologies and Management Options. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 968-981.	0.6	14
92	The Evolving State of Care for Acute Pulmonary Embolism. <i>Interventional Cardiology Clinics</i> , 2018, 7, xv-xvi.	0.2	0
93	Systemic Thrombolysis for Pulmonary Embolism. <i>Interventional Cardiology Clinics</i> , 2018, 7, 71-80.	0.2	7
94	Mechanical Circulatory Support for High-Risk Pulmonary Embolism. <i>Interventional Cardiology Clinics</i> , 2018, 7, 119-128.	0.2	6
95	Extra-corporeal membrane oxygenation and outcomes in massive pulmonary embolism: Two eras at an urban tertiary care hospital. <i>Vascular Medicine</i> , 2018, 23, 60-64.	0.8	25
96	Coronary atherectomy is associated with improved procedural and clinical outcomes among patients with calcified coronary lesions: Insights from the VA CART program. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1009-1017.	0.7	12
97	Genomic Risk Stratification Predicts All-Cause Mortality After Cardiac Catheterization. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002352.	1.6	16
98	Should Transcatheter Aortic Valve Replacement Be the Procedure of Choice for Intermediate-Risk Patients With Severe Aortic Stenosis?. <i>Circulation</i> , 2018, 138, 2624-2626.	1.6	0
99	Association Between 30-Day Mortality After Percutaneous Coronary Intervention and Education and Certification Variables for New York State Interventional Cardiologists. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006094.	1.4	4
100	Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 551-558.	1.0	2
101	Prasugrel or Ticagrelor for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1587-1589.	1.1	1
102	Trends in Platelet Adenosine Diphosphate P2Y <sub>12</sub> Receptor Inhibitor Use and Adherence Among Antiplatelet-Naïve Patients After Percutaneous Coronary Intervention, 2008-2016. <i>JAMA Internal Medicine</i> , 2018, 178, 943.	2.6	85
103	Contemporary Management and Outcomes of Patients with Massive and Submassive Pulmonary Embolism. <i>American Journal of Medicine</i> , 2018, 131, 1506-1514.e0.	0.6	79
104	Response by Hyman et al to Letter Regarding Article, "Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Insights From the National Cardiovascular Data Registry Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry". <i>Circulation</i> , 2018, 137, 2545-2546.	1.6	3
105	Risk of contrast-induced acute kidney injury in ST-elevation myocardial infarction patients undergoing multi-vessel intervention: meta-analysis of randomized trials and risk prediction modeling study using observational data. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 205-212.	0.7	16
106	Bioresorbable Scaffolds for Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2017, 19, 5.	1.3	4
107	Biomarkers of Calcific Aortic Valve Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 623-632.	1.1	63
108	Nitinol Self-Expanding Stents for the Superficial Femoral Artery. <i>Interventional Cardiology Clinics</i> , 2017, 6, 227-233.	0.2	6



#	ARTICLE	IF	CITATIONS
109	Interventional Treatment of Pulmonary Embolism. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	89
110	How Should We Address Carotid Artery Stenosis Around the Time of Open-Heart Surgery?. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 299-301.	1.1	2
111	Carotid Artery Stenting Versus Endarterectomy for Stroke Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2266-2275.	1.2	122
112	Anesthetic Evolution in Transcatheter Aortic Valve Replacement: Expert Perspectives From High-Volume Academic Centers in Europe and the United States. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 777-790.	0.6	42
113	Outcomes, readmissions, and costs in transfemoral and alternative access transcatheter aortic valve replacement in the US Medicare population. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1224-1232.e1.	0.4	24
114	Text mining applied to electronic cardiovascular procedure reports to identify patients with trileaflet aortic stenosis and coronary artery disease. <i>Journal of Biomedical Informatics</i> , 2017, 72, 77-84.	2.5	26
115	The Role of Embolic Protection in Carotid Stenting Progress in Cardiovascular Diseases (PCVD). <i>Progress in Cardiovascular Diseases</i> , 2017, 59, 612-618.	1.6	6
116	TAVR IS SAFE AND IMPROVES CARDIAC FUNCTION IN PATIENTS WITH EXTREMELY LOW EJECTION FRACTIONS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1035.	1.2	0
117	The Effect of Survivor Bias on Observational Analyses of Staged PCI in STEMI Patients. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 629-630.	1.1	4
118	Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 712-724.	1.1	56
119	Nuts and bolts of running a pulmonary embolism response team: results from an organizational survey of the National PERT Consortium members. <i>Hospital Practice (1995)</i> , 2017, 45, 76-80.	0.5	31
120	Meta-Analysis of Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Unprotected Left Main Coronary Artery Narrowing. <i>American Journal of Cardiology</i> , 2017, 119, 1746-1752.	0.7	17
121	Impact of Pulmonary Arterial Clot Location on Pulmonary Embolism Treatment and Outcomes (90 Days). <i>American Journal of Cardiology</i> , 2017, 119, 802-807.	0.7	21
122	Too Hot? Too Cold? When Is it "Just Right" to Stop Dual Antiplatelet Therapy After PCI With DES?. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1631-1632.	1.1	1
123	Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement. <i>Circulation</i> , 2017, 136, 2132-2140.	1.6	184
124	Robotic-assisted percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 948-955.	0.7	20
125	Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs Hospitals. <i>JAMA Cardiology</i> , 2017, 2, 967.	3.0	27
126	Cost and contribution margin of transcatheter versus surgical aortic valve replacement. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1872-1880.e1.	0.4	38



#	ARTICLE	IF	CITATIONS
127	The Role of the Pulmonary Embolism Response Team: How to Build One, Who to Include, Scenarios, Organization, and Algorithms. Techniques in Vascular and Interventional Radiology, 2017, 20, 216-223.	0.4	10
128	Intravenous fibrinolytics in STEMI: a 25-year perspective. Lancet, The, 2017, 390, 718-720.	6.3	2
129	Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications. Current Atherosclerosis Reports, 2017, 19, 56.	2.0	16
130	Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2017, 69, 367-377.	1.2	405
131	Aortic Stenosis: Pathophysiology, Diagnosis, and Therapy. American Journal of Medicine, 2017, 130, 253-263.	0.6	111
132	Effect of Chronic Kidney Disease on Mortality in Patients Who Underwent Lower Extremity Peripheral Vascular Intervention. American Journal of Cardiology, 2017, 119, 669-674.	0.7	16
133	Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. Thrombosis and Haemostasis, 2017, 117, 246-251.	1.8	51
134	Stent-based revascularization for complex lesions in PAD. Journal of Cardiovascular Surgery, 2017, 58, 715-721.	0.3	4
135	Is multivessel intervention in ST-elevation myocardial infarction associated with early harm? Insights from observational data. Catheterization and Cardiovascular Interventions, 2016, 88, 697-707.	0.7	4
136	Diversity in the Pulmonary Embolism Response Team Model. Chest, 2016, 150, 1414-1417.	0.4	72
137	Editorial Commentary: Guidance through the "Toolshed" for endovascular revascularization of the lower extremity. Trends in Cardiovascular Medicine, 2016, 26, 513-514.	2.3	0
138	Remote ischemic preconditioning in patients undergoing cardiovascular surgery: Evidence from a meta-analysis of randomized controlled trials. International Journal of Cardiology, 2016, 221, 34-41.	0.8	26
139	Coronary Stent Fracture. JACC: Cardiovascular Interventions, 2016, 9, 1124-1126.	1.1	4
140	Transfemoral transcatheter valve-in-valve-in-valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 622-623.	0.4	2
141	Building a Critical Limb Ischemia Program. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 50.	0.4	4
142	HAS-BLED Versus ATRIA Risk Scores for Intracranial Hemorrhage in Patients Receiving Thrombolytics for Pulmonary Embolism. Journal of the American College of Cardiology, 2016, 67, 2904-2905.	1.2	10
143	Does Surgical Repair of Moderate Ischemic Mitral Regurgitation Improve Survival? A Systematic Review. Current Cardiology Reports, 2016, 18, 22.	1.3	8
144	Insight into "Public" Reporting of Percutaneous Coronary Interventions in the State of Pennsylvania. American Journal of Cardiology, 2015, 116, 1645-1646.	0.7	0

#	ARTICLE	IF	CITATIONS
145	The Lariat for Left Atrial Appendage Closure: Rehash of Known Literature or a True Analysis?â€”Reply. JAMA Internal Medicine, 2015, 175, 1869.	2.6	0
146	Outcomes of transcatheter aortic valve replacement in patients with chronic liver disease. Catheterization and Cardiovascular Interventions, 2015, 86, 888-894.	0.7	21
147	Beyond Blood Pressure: Percutaneous Renal Denervation for the Management of Sympathetic Hyperactivity and Associated Disease States. Journal of the American Heart Association, 2015, 4, e001415.	1.6	14
148	Changes in Hospitalizations, Treatment Patterns, and Outcomes During Major Cardiovascular Meetings. JAMA Internal Medicine, 2015, 175, 1420.	2.6	3
149	Transradial Versus Transfemoral Access in Patients Undergoing Rescue Percutaneous Coronary Intervention After Fibrinolytic Therapy. JACC: Cardiovascular Interventions, 2015, 8, 1868-1876.	1.1	17
150	Coronary artery aneurysms associated with ascending aortic aneurysms and abdominal aortic aneurysms: Pathophysiologic implications. Catheterization and Cardiovascular Interventions, 2015, 85, 961-967.	0.7	21
151	Endovascular therapy for acute ischaemic stroke: a systematic review and meta-analysis of randomized trials. European Heart Journal, 2015, 36, 2373-2380.	1.0	70
152	Letter by Giri Regarding Article, “Comparative Effectiveness of Carotid Revascularization Therapies: Evidence From a National Hospital Discharge Database” Stroke, 2015, 46, e41.	1.0	1
153	Overestimation of Paravalvular Leak With Edwards SAPIEN 3 Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2015, 8, e69-e71.	1.1	1
154	Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device. JAMA Internal Medicine, 2015, 175, 1104.	2.6	57
155	Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia. Vascular Medicine, 2015, 20, 447-453.	0.8	26
156	Proximal Versus Distal Embolic Protection for Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2015, 8, 609-615.	1.1	43
157	Transcatheter Aortic Valve Replacement in Women. Journal of the American College of Cardiology, 2015, 66, 229-231.	1.2	2
158	Intervention strategies for multi-vessel disease in patients with ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. International Journal of Cardiology, 2015, 179, 225-227.	0.8	13
159	Unprotected carotid artery stenting in modern practice. Catheterization and Cardiovascular Interventions, 2014, 83, 595-602.	0.7	14
160	Factors Associated With Vascular Complications in Patients Undergoing Balloon-Expandable Transfemoral Transcatheter Aortic Valve Replacement via Open Versus Percutaneous Approaches. Circulation: Cardiovascular Interventions, 2014, 7, 570-576.	1.4	63
161	Blood pressure response to renal artery stenting in 901 patients from five prospective multicenter FDA-approved trials. Catheterization and Cardiovascular Interventions, 2014, 83, 603-609.	0.7	37
162	Early Aneurysm Formation After Everolimus-Eluting Stent Implantation. Circulation: Cardiovascular Interventions, 2014, 7, 266-267.	1.4	12

#	ARTICLE	IF	CITATIONS
163	Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage. JAMA - Journal of the American Medical Association, 2014, 311, 2414.	3.8	602
164	Benefits and Risks Associated With Thrombolysis for Pulmonary Embolismâ€”Reply. JAMA - Journal of the American Medical Association, 2014, 312, 1589.	3.8	1
165	Comparative Effectiveness of Commonly Used Devices for Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2014, 7, 171-177.	1.1	26
166	Patient radiation exposure during percutaneous endovascular revascularization of the lower extremity. Journal of Vascular Surgery, 2013, 58, 1556-1562.	0.6	24
167	Anatomic correlates of supraâ€œnormal ankle brachial indices. Catheterization and Cardiovascular Interventions, 2013, 81, 1025-1030.	0.7	26
168	Transcatheter Aortic Valve Replacement With Coronary Artery Protection Performed in a Patient With an Anomalous Left Main Coronary Artery. Journal of the American College of Cardiology, 2012, 60, e9.	1.2	13
169	Pre-procedural Risk Quantification for Carotid Stenting Using the CAS Score. Journal of the American College of Cardiology, 2012, 60, 1617-1622.	1.2	36
170	Procedural and clinical outcomes of the valveâ€œinâ€œvalve technique for severe aortic insufficiency after balloonâ€œexpandable transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2012, 80, 139-147.	0.7	17
171	Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population. Cytometry Part B - Clinical Cytometry, 2010, 78B, 329-337.	0.7	26
172	Premature peripheral arterial disease â€œ difficult diagnosis in very early presentation. International Journal of Angiology, 2009, 18, 45-47.	0.2	17
173	Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. Current Medical Research and Opinion, 2008, 24, 2509-2522.	0.9	35
174	Statin Use and Functional Decline in Patients With and Without Peripheral Arterial Disease. Journal of the American College of Cardiology, 2006, 47, 998-1004.	1.2	89